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Abstract Brown-Vialetto-Van Laere syndrome (BVVLS
[MIM 211530]) is a rare neurological disorder characterized
by infancy onset sensorineural deafness and ponto-bulbar
palsy. Mutations in SLC52A3 (formerly C20orf54), coding
for riboflavin transporter 2 (hRFT2), have been identified as
the molecular genetic correlate in several individuals with
BVVLS. Exome sequencing of just one single case revealed
that compound heterozygosity for two pathogenic mutations
in the SLC52A2 gene coding for riboflavin transporter 3
(hRFT3), another member of the riboflavin transporter fam-
ily, is also associated with BVVLS. Overexpression studies
confirmed that the gene products of both mutant alleles have
reduced riboflavin transport activities. While mutations in
SLC52A3 cause decreased plasma riboflavin levels, concordant
with a role of SLC52A3 in riboflavin uptake from food, the
SLC52A2-mutant individual had normal plasma riboflavin con-
centrations, a finding in line with a postulated function of
SLC52A2 in riboflavin uptake from blood into target cells.
Our results contribute to the understanding of human riboflavin
metabolism and underscore its role in the pathogenesis of
BVVLS, thereby providing a rational basis for a high-dose
riboflavin treatment.
Introduction
Since the first report by Brown in 1894 (Brown 1894) about
60 individuals suffering from BVVLS have been described
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(Sathasivam 2008). Age of onset varies from infancy to the
third decade. Progressive and severe sensorineural deafness
is the most frequently observed presenting symptom. Dur-
ing the invariably progressive course of the disease involve-
ment of the lower cranial nerves is observed in most affected
individuals and upper and lower motor neuron limb signs
are common neurological findings. Additional features
include but are not limited to cerebellar ataxia, sensory
neuropathy, optic atrophy, retinitis pigmentosa, mental
retardation, and psychiatric abnormalities. Diaphragmatic
paralysis causing respiratory compromise is a major
cause of death (Sathasivam 2008). The heterogenous
clinical spectrum overlaps with Fazio-Londe syndrome,
Madras motor neuron disease, Boltshauser syndrome,
amyotrophic lateral sclerosis, and Nathalie syndrome.
Mutations in SLC52A3 (GenBank accession no. NM_
033409), coding for human riboflavin transporter 2, have
been recently identified as the molecular genetic correlate in
a total of ten BVVLS index cases (Bosch et al 2011; Green
et al 2010; Anand et al 2012). These results are especially
important as they provide a mechanistic rational for a
high-dose riboflavin supplementation, which was indeed
effective in some individuals in improving the biochem-
ical and clinical condition (Bosch et al 2011; Anand et
al 2012).
Clinical data
Here, we report on a girl with a clinical presentation
consistent with BVVLS. She was born at 36 weeks of
gestation to healthy, unrelated parents. An older sister is
healthy. Her psychomotor development was normal until
the age of 3 years when her parents first noticed im-
paired hearing and walking, clumsiness, and vertical eye
movements. At 3 years and 2 months of age she was
admitted to hospital with acute onset truncal ataxia and
vertical nystagmus. Ophthalmologic examination showed
a beginning optic atrophy and impaired visual acuity.
Over the next 6 months behavioral abnormalities includ-
ing aggressive and auto-aggressive behavior developed,
her gait became wide based and frequent falls occurred.
The vertical nystagmus changed to chaotic eye move-
ments and progressive hearing loss necessitated the us-
age of sign language. There was no muscle weakness
and nerve conduction velocity (NCV) of the peroneal
nerve was normal (59 m/s, amplitude 3.9 mV). Howev-
er, her deep tendon reflexes in the lower extremities
were absent and NCV of the sural nerve was undetect-
able, indicating a sensory neuropathy. Extensive labora-
tory testing was noncontributory and analysis of
mitochondrial respiratory chain enzymes showed normal
activities of all complexes in muscle.
Unsteadiness gradually worsened and she was confined
to a wheelchair from the age of 5 years. Ophthalmologic
examination revealed a marked atrophy of the optic nerve. A
nervus suralis biopsy showed an axonal neuropathy without
signs of demyelination. Audiologic testing showed absent
acustic evoked potentials as well as absent potentials in
brainstem evoked response audiometry indicating retroco-
chlear deafness. Together with progressive hearing loss her
active speech production declined. Neurological examina-
tion at the age of 5.5 years showed a right-sided palsy of the
facial nerve and tongue wasting with fasciculations.
Methods and results
We performed exome sequencing using the Agilent Human
All Exon 50 Mb kit for targeted enrichment and subsequent
sequencing on the HiSeq2000 (Illumina) to identify the
disease causing mutations. Read alignment and variant call-
ing were performed as described previously (Mayr et al
2012). We produced a total of 12.5 Gb of mappable sequen-
ces and 92.8 % of the target was covered >20x. A filter for
genes carrying compound heterozygous and homozygous
variants absent from 1064 control exomes identified five
genes: TMCO4, OPN4, ABLIM1, FAM187B, and SLC52A2
(Table 1).
Given the role of impaired riboflavin transport in the
pathogenesis of BVVLS, one gene, SLC52A2 (GenBank
accession no. NM_024531), encoding human riboflavin
transporter 3 (hRFT3), clearly stood out. Both mutations,
c.368T>C, p.Leu123Pro and c.1016T>C, p.Leu339Pro, al-
ter amino acids evolutionarily conserved from human to
Danio rerio (Fig. 1). While the c.368T>C, p.Leu123Pro
mutation was absent from public single nucleotide polymor-
phism databases, the c.1016T>C, p.Leu339Pro variant
(rs148234606) was found 3 times in the heterozygous state
in 5375 exomes listed in the Washington Exome Variant
Server. Sanger sequencing confirmed the compound hetero-
zygous state of the mutations in the affected individual with
the mother being a heterozygous carrier of the c.1016T>C,
p.Leu339Pro and the father of the c.368T>C, p.Leu123Pro
mutation.
Table 1 Variants identified in individual #54994 by exome sequencing
Synonymous 11,199
NSV 10,486
NSV absent from 1046 controls 258
≥2 NSV/gene 5 (TMCO4, OPN4, ABLIM1,
FAM187B, SLC52A2)
NSV0missense, nonsense, stop loss, splice site disruption, insertions,
deletions
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In order to test the pathogenic impact of the mutations,
we next determined the in vitro function of the two mutated
hRFT3 proteins as described previously (Ho et al 2010). In
brief, the human SLC52A2 wildtype (wt) cDNA was subcl-
oned into pFLAG-CMV-6a expression vector (Sigma-
Aldrich, St. Louis, MO). Both mutations, c.368T>C and
c.1016T>C, were introduced by site-directed mutagenesis
with KOD-Plus-Mutagenesis Kit (TOYOBO, Osaka,
Japan) using following primer sets, forward primer
5′- CGGCATGCTGTGCCTCGAATGTCACT-3′, re-
verse primer 5′-GTGCCAGCACAAAGGCCAGTGC-
TAA-3 ′ f o r 368T>C , and fo rwa rd p r ime r 5 ′ -
CGGGCAGCCTCTCTCTGCTGGGCGTG-3′, reverse prim-
er 5′-GCCCTGCCAAGGACCTGCACAGCAC-3′ for
1016T>C. The mutations were confirmed by direct sequenc-
ing. HEK 293 cells were transfected with an empty vector and
vectors containing SLC52A2wt, SLC52A2368T>C, and
SLC52A21016T>C using Lipofectamine 2000 (Life Technolo-
gies, Carlsbad, CA). Forty-eight hours after the transfection,
the cells were used for the functional experiments. Cells were
incubated with 10 nM [3H]riboflavin (Moravek Biochemicals,
Inc., Brea, CA) for 1 min and, after washing and solubiliza-
tion, radioactivity was measured using liquid scintillation
counting.
Quantification of the cellular riboflavin uptake showed that
both mutations cause a significant decrease in the hRFT3
transporter activity, compared to wt transfectants, thereby sup-
porting pathogenicity (Fig. 2a). To confirm the transfection
efficiency of these cells, reverse transcriptase-PCR (RT-PCR)
analysis was carried out using the following primer sets, for-
ward primer 5′-GTGGCACCATGTGGCCCCAG-3′, reverse
primer 5′-CAACAGCAGCAGAAGACCCT-3′. The detailed
methods were previously described (Yonezawa et al 2008). The
RNA expressions of SLC52A2368T>C and SLC52A21016T>C
expressing cell were comparable to that of SLC52A2wt-
expressing cell (Fig. 2b). Native SLC52A2 was only slightly
observed in the cells transfected with empty vector.
Recent studies have shown that the metabolic profile of
BVVLS individuals mimics a mild form of multiple acyl-
Fig. 1 Structure of SLC52A2 and localization and conservation of
affected amino acid residues of identified mutations. Dark blue indi-
cates fully conserved amino acid residues, light blue marks amino
acids conserved in 60–80 % of species, white indicates residues con-
served in <60 % of species
Fig. 2 In vitro activity of mutant hRFT3. a Uptake of [3H]riboflavin
by HEK293 cells transfected with empty vector, SLC52A2wt (WT),
SLC52A2368T>C (L123P), and SLC52A21016T>C (L339P). The cells
were incubated in buffer (pH 7.4) containing 10 nM [3H]riboflavin
for 1 min at 37 °C. Each bar represents the mean ± SEM, n03. Data
were analyzed by Dunnett’s two-tailed test after one-way ANOVA. **
Different from vector-transfected cells, P<0.01. ## Different from
SLC52A2wt-transfected cells, P<0.01. b RNA expression of SLC52A2
in HEK293 cells transfected with empty vector, SLC52A2wt (WT),
SLC52A2368T>C (L123P), and SLC52A21016T>C (L339P). RT-PCR
analysis was carried out using specific primer sets. Products of
360 bp that corresponded to the SLC52A2 gene were separated by
1.5 % agarose gel electrophoresis and visualized by ethidium bromide
staining
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CoA dehydrogenation defects (MADD) (Bosch et al
2011). Analysis of plasma acylcarnitine levels in this
patient demonstrated moderately elevated levels of several
acylcarnitine and hydroxy-acylcarnitine species (Table 2).
We did not find any changes in urine organic acids and
plasma riboflavin, flavin mononucleotide (FMN) or flavin
adenine dinucleotide (FAD) concentrations (Table 3).
Based on our results and the positive response reported
in several BVVLS individuals (Anand et al 2012; Bosch
et al 2011), we started an oral riboflavin supplementation
(10 mg/kg body weight/day). Clinical and laboratory fol-
low up examination after 4 weeks showed that her fine
motor skills and assisted gait had improved, and levels of
most acylcarnitine species were now within normal range
(Table 2).
Discussion
Riboflavin, also known as vitamin B2, is a water-soluble
aromatic substance and has to be absorbed from the food. In
humans, at least two riboflavin transporters strongly
expressed in small intestine epithelial cells, hRFT1 and
hRFT2 encoded by SLC52A1 (GenBank accession no.
NM_017986) and SLC52A3, respectively, cooperatively
function in riboflavin uptake and subsequent distribution
into the blood (Yao et al 2010). Uptake into the target cells
from the blood might occur via passive diffusion but more
likely depends on specific transport systems (Foraker et al
2003). Inside the cells, riboflavin is converted into its bio-
active coenzymes FMN and FAD. The latter functions as an
electron acceptor for numerous dehydrogenases involved,
Table 2 Plasma acylcarnitines
(μmol/L) in individual #54994
before and after riboflavin treat-
ment compared to reported indi-
viduals (Pat 1-3) with SLC52A3
mutations (Bosch et al 2011)
Bold values are outside normal
range given in brackets.
w weeks, n.d. not determined
Treatment #54994 Normal range Pat 1 Pat 2 Pat 3 Normal range
No After 4 w No No No
C0 n.d. n.d. 18.3↓ 35.1 37.6 (22.0–55.0)
C2 8.39 6.50 (2.94–39.78) 3.2↓ 4.0 0.74↓ (3.4–13.0)
C3 0.38 0.30 (0.12–1.50) n.d. n.d. n.d.
C4 0.19 0.10 (0.06–0.89) 0.65↑ 2.97 0.43 (0.07–0.58)
C5 0.16 0.07 (0.03–0.49) 0.29↑ 1.99↑ 0.91↑ (0.04–0.22)
C6 0.07 0.04 (0.01–0.31) 0.27↑ 0.87↑ 0.02 (0.01–0.12)
C8 0.39 0.14 (0.05–0.94) 0.18 0.70↑ 0.53↑ (0.04–0.22)
C10 0.35 0.13 (0.05–0.67) 0.25 0.86 0.77 (0.04–0.30)
C10:1 0.35↑ 0.09 (0.02–0.28) n.d. n.d. n.d.
C10:2 1.70↑ 0.56 (0.03–1.15) n.d. n.d. n.d.
C12 0.08 0.02 (0.01–0.23) 0.15↑ 0.44↑ 0.64↑ (0.04–0.12)
C14 0.04 0.02 (0.01–0.23) 0.14↑ 0.23↑ 0.46↑ (<0.08)
C14:1 2.47↑ 0.69 (0.06–1.74) n.d. n.d. n.d.
C14:2 0.76↑ 0.41 (0.02–0.67) n.d. n.d. n.d.
C14-OH 0.24↑ 0.05 (<0.24) n.d. n.d. n.d.
C16 0.13 0.10 (0.06–0.73) 0.19 0.19 0.32↑ (0.06–0.24)
C16:1 0.45 0.32 (0.04–0.79) n.d. n.d. n.d.
C16-OH 0.19↑ 0.04 (<0.17) n.d. n.d. n.d.
C16:1-OH 0.11↑ 0.14↑ (<0.11) n.d. n.d. n.d.
C18:1 1.13 0.83 (0.11–2.27) 0.16 0.13 0.42↑ (0.06–0.28)
Table 3 Plasma riboflavin, FAD, and FMN levels (nmol/L) in individual #54994 before and after riboflavin treatment compared to reported
individuals (Pat 1-3) with SLC52A3 mutations (Bosch et al 2011)
Treatment #54994 Normal range Pat 1 Pat 2 Pat 3 Normal range
No After 4 w No No No
Riboflavin 7.4 132.7↑ 1.4↓ <1↓ 7.6 (3.9–49)
FMN 10.1 17.5↑ 1.7↓ <1↓ <1↓ (2.8–11.0)
FAD 325.6 399.7↑ (229.1–375.5) 31↓ 30↓ 24.5↓ (46–114)
Bold values are outside normal range given in brackets. w, weeks
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e.g., in mitochondrial fatty acid oxidation and branched
chain amino acid catabolism. In rats, severe riboflavin defi-
ciency mimics the metabolic signature of a multiple acyl-
coA dehydrogenation defect (MADD) (Goodman 1981).
Both, decreased levels of riboflavin and its metabolites and
biochemical findings suggestive for mild MADD have re-
cently been reported in hRFT2 mutant BVVLS individuals
(Bosch et al 2011). Plasma acylcarnitines and urine organic
acids levels were corrected to normal values upon oral
riboflavin supplementation and clinical features such as
muscle weakness improved within weeks (Anand et al
2012; Bosch et al 2011). In addition to these patients,
another study had investigated a patient with a complex
neonatal neurological disorder and a biochemical profile
suggestive for MADD (Ho et al 2010). Sequence analysis
of SLC52A1 revealed that the mother carried a heterozygous
deletion of exons 2 and 3. During pregnancy, this defect led
to a haploinsufficiency in riboflavin transport in the mother
with subsequent riboflavin deprivation of the infant. Clinical
signs and biochemical abnormalities completely resolved
after riboflavin treatment.
Here, we report causal mutations in a third member of the
riboflavin transporter family. SLC52A2 is located on chro-
mosome 8 and encodes a 445 amino acid protein containing
11 predicted membrane-spanning domains (Fig. 1). It has
been initially reported to act as a receptor for porcine en-
dogenous retrovirus subgroup A. Based on its amino acid
sequence similarity with hRFT1 (86.7 %) and hRFT2
(44.1 %) a physiological function in riboflavin transport
has been postulated and was subsequently confirmed by [3H]
riboflavin uptake experiments. The protein was therefore pro-
posed to be renamed hRFT3. Expression analysis had shown
that SLC52A2 is highly expressed in human brain and salivary
gland, whereas the other two members of the riboflavin trans-
porter family are strongly expressed in the small intestine.
These findings suggested a role of hRFT3 in brain riboflavin
homeostasis (Yao et al 2010). While mutant hRFT2
results in decreased plasma levels of riboflavin and its coen-
zyme forms FMN and FAD (Bosch et al 2011), ribofla-
vin and its derivates were within normal range in the
presented hRFT3-mutant individual. However, slightly
elevated acylcarnitine levels as found in patients with de-
creased levels of FAD argue for impaired riboflavin uptake
from the blood into the cell (Fig. 3). Of note, clinically
relevant disturbance of brain metabolism despite normal se-
rum levels has also been reported for another vitamin, thia-
mine. Missense mutations in SLC19A3, coding for human
thiamine transporter 2, cause a Wernicke encephalopathy-
like disease. Thiamine serum levels were normal and the
Fig. 3 Potential role of hRFT3 in riboflavin metabolism. Riboflavin is
taken up from nutrition and passed through into the blood by intestinal
epithelial cells. Proposed transporters involved are hRFT1 and hRFT2.
Uptake into the target cells might occur to a small amount via passive
diffusion but likely essentially relies on specific transport systems.
hRFT3 is highly expressed in the brain, concordant with an important
role in brain riboflavin homeostasis. In the cells, riboflavin is converted
into the dehydrogenation reaction coenzymes FMN and FAD. Lack of
FAD results in impaired acyl-CoA dehydrogenation leading to an
accumulation acylcarnitines as found in ETFDH or ETF mutant indi-
viduals presenting with MADD. Superfluous riboflavin undergoes
renal excretion. CACT, carnitine-acylcarnitine tranlsocase; CPT2, car-
nitine O-palmitoyl transferase 2; ETF, electron transfer flavoprotein;
ETFDH, ETF-dehydrogenase; MIM, mitochondrial inner membrane
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disorder was responsive to oral high-dose thiamine treatment
(Kono et al 2009).
An oral supplementation with riboflavin (10 mg/kg body
weight/day) has been initiated in the SLC52A2-mutant indi-
vidual presented in this study and led to a normalization of six
out of seven altered acylcarnitine species and moderate clin-
ical improvement. Nevertheless, longer follow up of a larger
cohort is necessary to judge the clinical effectiveness of ribo-
flavin in this subtype of BVVLS. Although our in vitro studies
indicate a residual function of hRFT3, one has to keep in mind
that the gradient from blood to brain is likely to be signifi-
cantly higher (Nagatsu et al 1967) than from intestine to
epithelial cells or blood. In addition, superfluous riboflavin
undergoes renal excretion thus limiting the possible increase
in blood riboflavin concentration by supplementation.
In summary, we demonstrate the power of next genera-
tion sequencing in the genetic diagnosis of rare metabolic
disorders providing the basis for a mechanistic therapy in
some cases, like in our patient a high-dose supplementation
with riboflavin. The causal nature of the mutations was
confirmed by in vitro analysis of transporter activities, there-
by substantiating the role of defective riboflavin transport in
the pathogenesis of BVVLS. The clinical overlap with mo-
tor neuron diseases such as amyotrophic lateral sclerosis
bridges the gap to more common disorders and a better
understanding of riboflavin metabolism might help to pin-
point the molecular defect in these entities while providing a
therapeutic perspective.
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